Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694967 · ClinicalTrials.gov registry record · NA
A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix
A NA study, sponsored by Lehigh Valley Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 92
- Enrollment target
NCT00694967 is a NA study that was terminated before completion, run by Lehigh Valley Hospital. The registered enrollment target is 92 participants.
The verdict
NCT00694967, a NA study, was terminated before completion, sponsored by Lehigh Valley Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
Study Summary
We hypothesized that weekly intramuscular injections of 17 hydroxyprogesterone caproate(17P) will reduce the number spontaneous preterm births prior to 35 weeks gestation when compared to cerclage therapy. The purpose of this study was to compare medical therapy with 17P to surgical therapy with transvaginal cerclage in patients with an ultrasound diagnosed short cervix and funnel in the mid-trimester.
Interventions
- PROCEDURE McDonald cerclage placement
- DRUG 17 hydroxyprogesterone caproate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00694967
The ClinicalTrials.gov registry entry for NCT00694967 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lehigh Valley Hospital, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which McDonald cerclage placement is the first listed.
NCT00694967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00694967 about?
NCT00694967 is a clinical study titled "A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix". We hypothesized that weekly intramuscular injections of 17 hydroxyprogesterone caproate(17P) will reduce the number spontaneous preterm births prior to 35 weeks gestation when compared to cerclage therapy. The purpose of this study was to compare medical therapy with 17P to surgical therapy with tra...
What is the current status of trial NCT00694967?
This trial is currently terminated. It is a NA study. The enrollment target is 92 participants. The study started on 2003-11. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00694967?
The interventions under investigation include: McDonald cerclage placement (PROCEDURE), 17 hydroxyprogesterone caproate (DRUG).
Who is sponsoring clinical trial NCT00694967?
This trial is sponsored by Lehigh Valley Hospital, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.